Loading clinical trials...
Loading clinical trials...
A Phase I/II Clinical Study Evaluating the Safety and Preliminary Efficacy of EXG202 in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Conditions
Interventions
EXG202 injection
Start Date
October 16, 2025
Primary Completion Date
February 28, 2028
Completion Date
December 30, 2032
Last Updated
September 17, 2025
NCT05407636
NCT06859515
NCT06718816
NCT04932980
NCT07389577
NCT05381948
Lead Sponsor
Guangzhou Jiayin Biotech Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions